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GENENTECH IS GRATIFIED TO BE THE FIRST
BIOTECHNOLOGY COMPANY TO HAVE CONDUCTED
A LIFE SCIENCES EXPERIMENT IN MICROGRAVITY.
AMERICANS HAVE DISCOVERED AND APPLIED MOST
OF THE PREEMINENT SCIENTIFIC AND
TECHNOLOGICAL ACHIEVEMENTS OF THIS
CENTURY, INCLUDING THE GENETIC ENGINEERING
OF PROTEINS FOR HUMAN HEALTH APPLICATIONS.
WE MUST IMPROVE OUR ABILITY TO RAPIDLY
TRANSLATE ADVANCES IN PROCESS AND
BIOLOGICAL SCIENCES INTO ECONOMIC AND




GENENTECH DISCOVERS AND PRODUCES BY
RECOMBINANT DNA TECHNOLOGY
PHARMACEUTICALS FOR HUMAN HEALTH.
1989 REVENUES OF $476 MILLION
GROWTH HORMONE, TISSUE PLASMINOGEN
ACTIVATOR AND GAMMA-INTERFERON ARE
APPROVED BY THE FDA FOR TREATING GROWTH
HORMONE INADEQUACY IN CHILDREN, HEART
ATTACK AND CHRONIC GRANULOMATOUS
DISEASE IN CHILDREN, RESPECTIVELY
PARTIAL LIST OF PROTEINS IN CLINICAL TRIALS:
DNASE FOR CYSTIC FIBROSIS
INSULIN-LIKE GROWTH FACTOR FOR
DIABETES
RELAXIN TO FACILITATE CHILDBIRTH
HER-2 FOR BREAST AND OVARIAN CANCER
CRONIN
5-14-91
--' 40% OF OUR REVENUES REINVESTED IN R & D,
TWICE THAT OF OUR NEXT COMPETITOR
2100 EMPLOYEES; 27% HAVE ADVANCED
DEGREES
~ 1,500 PEER REVIEWED ARTICLES PUBLISHED
IN THE PUBLIC LITERATURE BY GENENTECH
SCIENTISTS SINCE 1977




HISTORY OF PHYSIOLOGICAL SYSTEMS
EXPERIMENT (PSE - 01)
1988 PENN STATE CCDS CONTACTS GENENTECH
1989 GENENTECH MEETS WITH NASA- AMES
RESEARCH CENTER SCIENTISTS AND
ADMINISTRATORS
GENENTECH, AMES AND PENN STATE
PRESENT PLAN TO MR. JAMES ROSE
MANIFESTED ON STS-41 IN DECEMBER
1 990 FLIGHT CREW TRAINED FOR PSE-01




WE ARE INTERESTED IN THE REPORTS OF BONE AND
MUSCLE WAISTING, AS WELL AS IMMUNE CELL
DYSFUNCTION, THAT OCCUR IN MICROGRAVITY.
A NUMBER OF HUMAN DISORDERS ARE
ASSOCIATED WITH MALADAPTIVE CHANGES
IN BONE, MUSCLE AND IMMUNE FUNCTION.
THE ADJUSTMENTS TO SPACE FLIGHT MAY AID
IN THE DISCOVERY OF NEW PROTEIN FORMS
AND PATTERNS. THIS RESEARCH MAY ALSO
PROVIDE STRATEGIES FOR PROTECTING THE
HEALTH OF FLIGHT CREWS ENDURING
PROLONGED SPACE FLIGHT.
WE MEASURED THE LEVEL OR EFFECT OF A NUMBER




PRECIOUS LITTLE IS KNOWN ABOUT
PHYSIOLOGIC ADJUSTMENTS TO
MICROGRAVlTY.
THUS, OUR ABILITY TO CONTROL SOME
IMPORTANT EXPERIMENTAL VARIABLES, AND TO
PREDICT THE COMMERCIAL OPPORTUNITY, WAS
LIMITED BY LACK OF EXPERIENCE AND
KNOWLEDGE.




PSE-01 FLEW AND LANDED ON TIME !
HEALTHY SPECIMENS WERE
RETURNED TO US FOR ANALYSIS.









































































NASA HEADQUARTERS, ARC, KSC AND JSC
PENN STATE CCDS
KIRK RAAB AND THE EXECUTIVE MANAGEMENT
OF GENENTECH
DEDICATION
PSE-01 IS DEDICATED TO THE MEMORY OF
MATTHEW MATLOCK, WHO DIED AT BIRTH DURING
THE FLIGHT OF DISCOVERY.
